The results showed that Chr-A treatment caused a remarkably elevated ratio of caspase 9/caspase 9, as well as an elevated expression ratio of cleaved caspase 3/caspase 3, cleaved caspase 7/caspase 7 in glioblastoma cells of tumor tissues, which are executives downstream of the apoptotic process (Figure 6A,B). The gene discussed is CASP3; the disease is glioblastoma.